comparemela.com

Latest Breaking News On - Mary relling - Page 2 : comparemela.com

Precision Medicine Blueprint Created for Childhood Leukemia

Precision Medicine Blueprint Created for Childhood Leukemia
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

To wipe childhood cancer off map, scientists must chart its genomic landscape

To wipe childhood cancer off map, scientists must chart its genomic landscape
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Inherited gene variant powers up an oncogene to drive high-risk leukemia

Jun J. Yang, Ph.D., St. Jude departments of Oncology and Pharmaceutical Sciences, is co-corresponding author of the new paper published in Nature

Analysis reveals origins of a leukemia that straddles diagnostic categories

Analysis reveals origins of a leukemia that straddles diagnostic categories
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Risk-directed childhood leukemia treatment takes a step forward

Date Time Risk-directed childhood leukemia treatment takes a step forward Corresponding author Ching-Hon Pui, M.D., St. Jude Oncology Department chair, helped discover how genomic analysis can improve outcomes for children with acute lymphoblastic leukemia. Comprehensive genomic analyses have helped researchers identify more than 20 subtypes of acute lymphoblastic leukemia (ALL) based on the genetic mutations that drive the disease. Research led by St. Jude Children’s Research Hospital scientists showed that combining these data with leukemia response measurements improves prediction of relapse risk. Currently, patients’ response to treatment influences the type of therapy administered for ALL. This risk-directed approach involves assessing minimal residual disease, the level of leukemic cells in the blood or bone marrow of patients at defined points during treatment

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.